10-Q quarterly report · filed Nov 9, 2026

Perspective Therapeutics, Inc. (CATX) Q3 2026 10-Q Quarterly Report

Short answer

Perspective Therapeutics, Inc. (CATX) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$32M
−24.9% YoY · −21.1% QoQ
EPS (diluted)
−$0.27
+22.9% YoY · −22.7% QoQ

Source: XBRL data from the Perspective Therapeutics, Inc. (CATX) Q3 2026 10-Q on SEC EDGAR. USD.

Perspective Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Grant revenue $0.2 million lower YoY; operating loss $34.3 million vs $27.9 million
  • R&D expenses $26.1 million, up $5.8 million YoY, driven by clinical and manufacturing investment
  • VMT-α-NET strongest program: Cohort 3 disease control 95%, versus Cohort 2 at 89%
  • Cash, equivalents and short-term investments $201.7 million; operating cash use $83.5 million through nine months
  • Expenses expected to rise; funding sufficient into 2028, with additional capital likely required before profitability

Risk Factors

  • No material changes to 2025 Form 10-K risk factors
  • Carried-forward risk: unidentified or presently unknown risks could materially adversely affect business
  • Market risk: securities price could decline significantly or permanently
  • General business risk: identified risks could materially adversely affect financial condition and results of operations

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Perspective Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.